Nicholas M Burgess1, Wendy Kelso1, Charles B Malpas2,3,4, Toby Winton-Brown4, Timothy Fazio5,6, Julie Panetta5, Gerard De Jong5, Joanna Neath1, Sonny Atherton7, Dennis Velakoulis1,8, Mark Walterfang9,10,11. 1. Neuropsychiatry Unit, Royal Melbourne Hospital, Level 2, John Cade Building, Melbourne,, 3050, Australia. 2. Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia. 3. Clinical Outcomes Research Unit (CORe), Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia. 4. Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 5. Department of Metabolic Medicine, Royal Melbourne Hospital, Melbourne, Australia. 6. Melbourne Medical School, Department of Medicine and Radiology, University of Melbourne, Parkville, Australia. 7. Gold Coast University Hospital, Southport, Australia. 8. Melbourne Neuropsychiatry Centre, University of Melbourne and North-Western Mental Health, Melbourne, Australia. 9. Neuropsychiatry Unit, Royal Melbourne Hospital, Level 2, John Cade Building, Melbourne,, 3050, Australia. mark.walterfang@mh.org.au. 10. Melbourne Neuropsychiatry Centre, University of Melbourne and North-Western Mental Health, Melbourne, Australia. mark.walterfang@mh.org.au. 11. Florey Institute of Neuroscience and Mental Health, Melbourne, Australia. mark.walterfang@mh.org.au.
Abstract
BACKGROUND: Phenylketonuria (PKU) is an autosomal recessive inherited disorder characterised by a deficiency in phenylalanine hydroxylase. Untreated, PKU is associated with a wide range of cognitive and psychiatric sequelae. Contemporary management guidelines recommend lifetime dietary control of phenylalanine (Phe) levels, however many individuals who discontinue dietary control subsequently suffer symptoms of anxiety, depression and disturbances to cognition. We undertook a prospective cohort study of patients with early-treated phenylketonuria who had ceased dietary control to test the hypothesis that resumption of dietary control of PKU is associated with improvements in measures of psychiatric morbidity and cognitive functioning. METHODS: We re-initiated dietary control for early-treated patients with PKU and monitored cognitive and psychiatric outcomes over a twelve-month period. Assessments included objective cognitive function (measured by cognitive proficiency index (CPI)), anxiety and depression scales. General linear mixed model (GLMM) analyses were performed to assess change in psychometric variables from baseline over twelve months after resumption of dietary control. RESULTS: A total of nine patients were recruited. Mean age was 33 years (SD = 8.75), five were female. Mean time off dietary control was 19.1 years (SD = 11.3), and mean baseline phenylalanine (Phe) levels were 1108 µmol/L (SD = 293). GLMM analysis demonstrated a positive relationship between CPI and time on diet (b = 0.56 [95% CI = 0.17, 0.95]). Age, time off diet, Phe levels and depression scores were not associated with cognitive function. There was a negative relationship between time on diet and anxiety (b = - 0.88 95% CI = [- 1.26, - 0.50]) and depression ratings (b = - 0.61, 95% CI = [- 0.95, - 0.26]). CONCLUSIONS: This study demonstrated improvements in cognitive function, anxiety, and depression ratings associated with resumption of dietary control of PKU. Raw Phe levels were not strongly associated with psychiatric or cognitive scores in this cohort. These findings support the importance of lifelong treatment for PKU in improving the cognitive and psychiatric sequelae of the disease.
BACKGROUND:Phenylketonuria (PKU) is an autosomal recessive inherited disorder characterised by a deficiency in phenylalanine hydroxylase. Untreated, PKU is associated with a wide range of cognitive and psychiatric sequelae. Contemporary management guidelines recommend lifetime dietary control of phenylalanine (Phe) levels, however many individuals who discontinue dietary control subsequently suffer symptoms of anxiety, depression and disturbances to cognition. We undertook a prospective cohort study of patients with early-treated phenylketonuria who had ceased dietary control to test the hypothesis that resumption of dietary control of PKU is associated with improvements in measures of psychiatric morbidity and cognitive functioning. METHODS: We re-initiated dietary control for early-treated patients with PKU and monitored cognitive and psychiatric outcomes over a twelve-month period. Assessments included objective cognitive function (measured by cognitive proficiency index (CPI)), anxiety and depression scales. General linear mixed model (GLMM) analyses were performed to assess change in psychometric variables from baseline over twelve months after resumption of dietary control. RESULTS: A total of nine patients were recruited. Mean age was 33 years (SD = 8.75), five were female. Mean time off dietary control was 19.1 years (SD = 11.3), and mean baseline phenylalanine (Phe) levels were 1108 µmol/L (SD = 293). GLMM analysis demonstrated a positive relationship between CPI and time on diet (b = 0.56 [95% CI = 0.17, 0.95]). Age, time off diet, Phe levels and depression scores were not associated with cognitive function. There was a negative relationship between time on diet and anxiety (b = - 0.88 95% CI = [- 1.26, - 0.50]) and depression ratings (b = - 0.61, 95% CI = [- 0.95, - 0.26]). CONCLUSIONS: This study demonstrated improvements in cognitive function, anxiety, and depression ratings associated with resumption of dietary control of PKU. Raw Phe levels were not strongly associated with psychiatric or cognitive scores in this cohort. These findings support the importance of lifelong treatment for PKU in improving the cognitive and psychiatric sequelae of the disease.
Authors: Janet Thomas; Harvey Levy; Stephen Amato; Jerry Vockley; Roberto Zori; David Dimmock; Cary O Harding; Deborah A Bilder; Haoling H Weng; Joy Olbertz; Markus Merilainen; Joy Jiang; Kevin Larimore; Soumi Gupta; Zhonghua Gu; Hope Northrup Journal: Mol Genet Metab Date: 2018-03-31 Impact factor: 4.797
Authors: Deborah A Bilder; Joyce A Kobori; Jessica L Cohen-Pfeffer; Erin M Johnson; Elaina R Jurecki; Mitzie L Grant Journal: Mol Genet Metab Date: 2017-03-06 Impact factor: 4.797
Authors: A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen Journal: Orphanet J Rare Dis Date: 2017-10-12 Impact factor: 4.123
Authors: B K Burton; D K Grange; A Milanowski; G Vockley; F Feillet; E A Crombez; V Abadie; C O Harding; S Cederbaum; D Dobbelaere; A Smith; A Dorenbaum Journal: J Inherit Metab Dis Date: 2007-09-12 Impact factor: 4.982
Authors: Killian Ashe; Wendy Kelso; Sarah Farrand; Julie Panetta; Tim Fazio; Gerard De Jong; Mark Walterfang Journal: Front Psychiatry Date: 2019-09-10 Impact factor: 4.157
Authors: Deborah A Bilder; Georgianne L Arnold; David Dimmock; Mitzie L Grant; Darren Janzen; Nicola Longo; Mina Nguyen-Driver; Elaina Jurecki; Markus Merilainen; Gianni Amato; Susan Waisbren Journal: Am J Med Genet A Date: 2021-11-26 Impact factor: 2.578